Advanced searches left 3/3
Search only database of 12 mil and more summaries

Venlafaxine For Hot Flashes

Summarized by PlexPage
Last Updated: 18 January 2022

* If you want to update the article please login/register

General | Latest Info

Study Has Found That Antidepressant Effexor Eases Hot Flashes Just As Well As Hormone Replacement Therapy. There are types of antidepressant Medicines: SSRIs and SNRIs. Effexor is SNRI. Research Was Published Online On May 26 2014 By JAMA Internal Medicine. Read abstract of Low-Dose Estradiol Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms: randomize Clinical Trial. Menopausal symptoms such as hot flashes and night sweats can dramatically reduce quality of life for some women. Hot Flashes are are known side effect of hormonal therapy medicines used to treat Breast Cancer. Doctors call Hot Flashes night sweats Vasomotor Symptoms. Some women use hormone replacement therapy to these symptoms. But research has that HRT increases Breast Cancer risk in women who haven't been diagnose. HRT also increases risk of Breast Cancer coming back in women who have been diagnosed with disease. HRT is not for women who have been diagnosed with Breast Cancer. Undiagnosed Women who have severe menopausal symptoms need to weigh benefits of HRT against its risks. It is not clear if any of 339 women in this study had been diagnosed with Breast Cancer or were at high risk for disease. Women were having at least Hot Flashes per day and most were having about eight. Women were randomly assigned to receive one of three treatments daily for 8 weeks: Low-Dose estrogen-only HRT 75 mg Effexor placebo after 8 weeks, number of Flashes per day most women having dropped from eight to four-50 percentage decrease. HRT reduces Flashes by 52. 9 percentage . Effexor reduced Hot by 47. 6 percentage . Placebo reduces Flashes by 28. 6 percentage . Difference In Hot Flash Reduction Between HRT And Effexor Wasnt Significant, Which Means That It Could Have Happened By Chance And Wasnt Necessarily Because Of Difference In Medicine. In 2013, US Food and Drug Administration approved Low-Dose formula of another antidepressant, Paxil, under brand name Brisdelle, to treat Hot Flashes. Paxil is SSRI. FDA approval was based research comparing Paxil to placebo pill. Study Review Here Is First Time Researchers Have Compared Antidepressants To HRT To Treat Hot Flashes. Other research has suggested that other Antidepressants may help ease Hot Flashes, including SSRIs: Prozac lexapro celexa Some these Antidepressants may cause problems for women taking tamoxifen. Enzyme Called CYP2D6 Helps Tamoxifen Work In Body. Some research has shown that women with abnormal genes that block their body's ability to produce CYP2D6 do get same benefits from tamoxifen as women who produce CYP2D6. Other research has that some Medicines-including Antidepressants Paxil and Prozac-can interfere with how CYP2D6 works and might reduce tamoxifens effectiveness against Breast Cancer. Still, subject is controversial and not all experts agree that lack of CYP2D6 or taking reduces tamoxifens effectiveness.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Question

This is first trial to simultaneously investigate efficacy of low-dose oral estradiol and SNRI Venlafaxine on quality of life related to Menopause using MENQOL and validated measures of pain, anxiety, depression and stress in peri-and postmenopausal women with bothersome VMS. In this double-blind, placebo control randomized trial of healthy midlife women with VMS and without evidence of major depression, treatment with both low-dose estradiol and Venlafaxine significantly improved overall quality of life. For estrogen, beneficial treatment effects were seen in all domains of MENQOL except psychosocial, while for Venlafaxine, benefits were observed only in psychosocial domain. Venlafaxine also improves perceived stress. Neither agent improves pain, depressive or anxious symptoms in this general population of women not selected on basis of these specific symptoms. Of note is that Venlafaxine reduced VMS frequency and severity compared to placebo in our primary trial analyses but in this study do not see improvement in VMS domain on MENQOL. This suggests that way MENQOL asks about VMS elicits information differently than number and severity of events and that these aspects of VMS may be more importantly tied to improving quality of life. In addition, it is interesting to note that while improvement with Venlafaxine in psychosocial domain was only one that reached statistical significance, all other domains also improved with Venlafaxine while not reaching statistical significance, thus contributing to statistically significant improvement in overall QOL. Two other trials, but with slightly different patient populations, provide insight improvements in MENQOL following treatment with estrogen formulations. In trial of 318 women with seven or more moderate-to-severe VMS daily, treatment with bazedoxifene 20 mg / day plus conjugated estrogen resulted in significant improvements in total and domain-specific MENQOL scores. Both lower dose and higher estrogen treatment groups show significant improvements in vasomotor and total scores on MENQOL questionnaire relative to placebo. However, participants treated with BZA 20 mg / CE 0. 625 mg also had significant improvements in psychosocial, physical, and sexual scores compared with placebo. In second smaller trial, among 32 women with depressive disorders as well as Menopause Symptoms, ethinyl estradiol 5 ug / day plus norethindrone acetate 1 mg / day, was directly compared to escitalopram, SSRI rather than SNRI antidepressant evaluated in present study. Improvements in MENQOL total and domain scores were statistically similar, but treatment with escitalopram resulted in greater improvements than estradiol on psychosocial domain, similar to findings in present trial. In double-blind, placebo-control randomized trial of SSRI escitalopram, / day vs. Identical placebo, among 205 women aged 40-62 years with average of 4 daily hot flashes, treatment with escitalopram, similar to results seen in this study, resulted in significantly greater improvement in total MENQOL scores. In that study, escitalopram also improved scores in vasomotor, psychosocial, physical domains of MENQOL which were not seen with SNRI Venlafaxine in our study.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Continued

One of first trials to assess efficacy of Venlafaxine for treatment of hot flashes is extension of pilot study that showed promising results. Randomize, Double-blind, Placebo-control Trial Included 221 Women With History Of Breast Cancer Or Fear Of Developing Breast Cancer As Result Of Taking Estrogen. 16 To be include, women to have at least 14 troublesome hot flashes per week, occurring for at least one month. Participants were assigned to receive Venlafaxine 37. 5 mg, 75 150 mg, or placebo daily for 4 weeks. Participants keep hot flash diaries every day for 1 week at baseline and during treatment period. Diaries were used to calculate hot flash scores, which combine number and severity of hot flash episodes. After 4 weeks of all three Venlafaxine groups had significantly greater reductions compared to placebo. Median score were 37 percent, 61 percent, and 61 percent for Venlafaxine 37. 5 mg, 75 mg, and 150 groups compared to only 27 percent for placebo. As Venlafaxine dose increase, hot flash activity significantly decrease, with exception of 150 mg group. In terms of toxicity, significantly more nausea, dry mouth, appetite loss, and constipation were reported in 75 mg and 150 mg groups, with most occurring in latter. Base on results of this trial, it seems 75 mg is preeminent dose, being that it is more effective than 37. 5 mg and less than 150 mg dose. Strengths of this trial were design, large sample size, and doses were titrate to improve toleration. Short duration lack or reporting baseline characteristics were limitations. 12-week, randomize, control trial looked at efficacy of extend-release Venlafaxine in 80 women with natural or surgical menopause. 4 women were required to experience at least 14 hot flashes per week and were excluded for taking any hormone, antidepressant, chemotherapy agents. Participants were to receive either Venlafaxine 37. 5 mg daily for 1 week, then 75 mg daily for 11 or placebo. Daily hot flash severity scores were by participants, along with completion of monthly questionnaires. Study Was Completed By 61 Participants, 29 In Treatment Group And 32 In Control Group. At week 4, patient-perceive hot flash score had declined in both Venlafaxine and placebo groups, but there was no significant difference between two. At week 12, mean score for Venlafaxine group further decline, while control group rebound. These correspond to 51 percent reduction in patient-perceive hot flash score for Venlafaxine group, compared to 15 percent reduction with placebo. Although dry mouth, loss of appetite, and sleeplessness were commonly observed side effects, 93 percent of participants in Venlafaxine group chose to continue treatment at conclusion of trial. This illustrates that most women feel benefits of Venlafaxine therapy outweigh risk of adverse effects.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2022 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.